Sophia Genetics' New AI Leukemia Diagnostics Test is Available in Europe

Sophia Genetics has received a CE-IVD mark for its molecular diagnostics test, which will improve the detection of leukemia. Swiss company Sophia Genetics is a leader in the field of data-driven medicine, with its artificial intelligence (AI) technology already been used to analyze the next-generation sequencing data of over 160,000 patients' around the world. Today, the company has received a CE-IVD mark for its molecular diagnostics tool, meaning it can be traded within the European single market. The technology reads the genome more precisely to improve the diagnosis of leukemia and boost the personalization of cancer care. By receiving a CE mark, the company now has permission to trade its product within the European single market as it has shown no adverse effects on human health or the environment.